Efficacy of famotidine 20 mg twice a day versus 40 mg twice a day in the treatment of erosive or ulcerative reflux esophagitis

Digestive Diseases and Sciences

Volumn 38, Issue 12, 1993, Pages 2287-2293

  Wesdorp, I C E ^a,b,c   Dekker, W ^a,b,c   Festen, H P M ^a,b,c  

^a Department of Gastroenterology   (Netherlands)

^b Elisabeth Gasthuis ^*  (Netherlands)

^c JEROEN BOSCH HOSPITAL   (Netherlands)

Author keywords

erosive ulcerative reflux esophagitis; famotidine

Indexed keywords

FAMOTIDINE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ENDOSCOPY; ESOPHAGUS BURN; ESOPHAGUS ULCER; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REFLUX ESOPHAGITIS; ULCER HEALING; VERTIGO;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ESOPHAGITIS, PEPTIC; ESOPHAGOSCOPY; FAMOTIDINE; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TIME FACTORS; ULCER;

EID: 0027724069     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/BF01299910     Document Type: Article

References (38)

1. Treatment of reflux esophagitis with H2-blockers, antacids and prokinetic drugs
2. Treatment of reflux esophagitis with H2-receptor antagonists
3. Histamine H2-receptor antagonists in gastro-oesophageal reflux
4. Healing and relapse rate of reflux oesophagitis during treatment with ranitidine
5. Acute treatment of reflux oesophagitis: A multi-centre trial to compare 150 mg ranitidine bd with 300 mg ranitidine qds
6. The effect of omeprazole or ranitidine treatment on 24-hour esophageal acidity in patients with reflux esophagitis
7. Investigation of ranitidine 150 mg bd or 300 mg bd in the treatment of reflux disease
8. A comparison of two doses of nizatidine versus placebo in the treatment of reflux oesophagitis
9. Omeprazole and ranitidine in treatment of reflux oesophagitis: double blind comparative trial
10. Double blind comparison of omeprazole (40 mg od) versus cimetidine (400 mg qd) in the treatment of symptomatic erosive reflux oesophagitis, assessed endoscopically, histologically and by 24 h pH-monitoring
11. Omeprazole in the treatment of erosive oesophagitis refractory to high dose cimetidine and ranitidine
12. Comparison of omeprazole and cimetidine in reflux oesophagitis: Symptomatic, endoscopic, and histological evaluations
13. Efficacy of different doses of cimetidine in the treatment of reflux oesophagitis. A review of three large, double-blind, controlled trials
14. Symptoms and endoscopic findings in the diagnosis of gastroesophageal reflux disease
15. When is esophagitis healed? Esophageal endoscopy, histology, and function before and after cimetidine treatment
16. Endoscopy of the oesophagus
17. Medical therapy of reflux esophagitis
18. Double-blind multicentre comparison of omeprazole and ranitidine in the treatment of reflux oesophagitis
19. Daytime gastro-oesophageal reflux is important in oesophagitis
20. Reflux patterns and related oesophageal motoractivity in gastro-oesophageal reflux disease
21. Technique, indications and clinical use of 24 hour esophageal pH-monitoring
22. Acid reflux and oesophagitis—day or night?
23. Daytime reduction of gastro-oesophageal reflux after healing of oesophagitis and its value as an indicator of favourable response to maintenance treatment
24. Gastric and esophageal acidity during continuous treatment with H2-antagonists in uncomplicated esophagitis
25. Dose response effects of famotidine on patterns of gastro-oesophageal reflux
26. Gastric secretion and reflux pattern in reflux oesophagitis before and during ranitidine treatment
27. Gastric acid hypersecretion in refractory gastroesophageal reflux disease
28. Omeprazole or ranitidine in the treatment of reflux esophagitis
29. Effect of increasing doses of ranitidine on exposure of the oesophagus to gastric acid in patients with reflux oesophagitis
30. Famotidine, a new, potent, long-acting histamine H2-receptor antagonist: Comparison with cimetidine and ranitidine in the treatment of Zollinger-Ellison syndrome
31. Mk-208, a novel histamine H2-receptor antagonist inhibitor with prolonged anti-secretory effects
32. Bid regimens of an H2-receptor antagonist heal erosive esophagitis: Results of a US, double-blind, randomized, multi-center trial
33. High dose famotidine in ranitidine resistant severe oesophagitis: A pilot study
34. Results of an international double-blind, multicenter trial comparing BID dosages of H2-receptor antagonists: Relationship between pharmacodynamic effect on esophageal reflux and healing of erosive esophagitis
35. Oral cimetidine in reflux esophagitis: A double blind controlled trial
36. The place of famotidine in anti-ulcer therapy
37. Human gastric alcohol dehydrogenase: Its inhibition by H2-receptor antagonists, and its effects on the bioavailability of ethanol